Who Paid My Doc
Fereshteh Sani
Emergency Medicine Mc Lean, VA Medical Doctor
NPI 1467742312 CMS profile 2858988
8008 Westpark Dr, Mc Lean, VA 22102
General payments
$13,233
Research payments
$0
Ownership & investment interest
$0
Through program year 2019, Fereshteh Sani of Mc Lean, VA is reported in the CMS Open Payments database as having received $13,233 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 98th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2019 | General | $13,233 | 1 |
Beside peers
- Fereshteh Sani
- Emergency Medicine median
- Middle half of Emergency Medicine
- National median
In program year 2025, general payments to Fereshteh Sani were reported at $0. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.
Show as a table
| Year | Fereshteh Sani | Emergency Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $13,233 | $51 | $18–$128 | $163 |
| 2020 | $0 | $29 | $16–$99 | $114 |
| 2021 | $0 | $40 | $18–$124 | $132 |
| 2022 | $0 | $49 | $20–$134 | $149 |
| 2023 | $0 | $51 | $22–$142 | $160 |
| 2024 | $0 | $52 | $22–$150 | $164 |
| 2025 | $0 | $57 | $24–$150 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
53
Drug cost
$415
Branded share of claims
75.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 17 | $154 | |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | Brand | 23 | $146 | |
| Doxycycline Monohydrate | Generic | 13 | $115 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Emergency Medicine in Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Emergency Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.